Phascolarctobacterium faecium
Selected indexed studies
- Gut commensal Phascolarctobacterium faecium retunes innate immunity to mitigate obesity and metabolic disease in mice. (Nat Microbiol, 2025) [PMID:40328980]
- Phascolarctobacterium faecium abundant colonization in human gastrointestinal tract. (Exp Ther Med, 2017) [PMID:28912861]
- Phascolarctobacterium faecium reduces food intake via PYY signaling, contributing to the mitigation of body weight gain in diet-induced obese mice. (Gut Microbes, 2026) [PMID:41566927]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Fecal microbiota transplantation promotes reduction of antimicrobial resistance by strain replacement. (2023) pubmed
- Gut commensal Phascolarctobacterium faecium retunes innate immunity to mitigate obesity and metabolic disease in mice. (2025) pubmed
- Phascolarctobacterium faecium abundant colonization in human gastrointestinal tract. (2017) pubmed
- Phascolarctobacterium faecium reduces food intake via PYY signaling, contributing to the mitigation of body weight gain in diet-induced obese mice. (2026) pubmed
- Microbial interaction between the succinate-utilizing bacterium Phascolarctobacterium faecium and the gut commensal Bacteroides thetaiotaomicron. (2020) pubmed
- Complete Genome Sequence of Phascolarctobacterium faecium JCM 30894, a Succinate-Utilizing Bacterium Isolated from Human Feces. (2019) pubmed
- Complete Genome Sequence of Phascolarctobacterium faecium G 104, Isolated from the Stools of a Healthy Lean Donor. (2021) pubmed
- Intermittent fasting, calorie restriction, and a ketogenic diet improve mitochondrial function by reducing lipopolysaccharide signaling in monocytes during obesity: A randomized clinical trial. (2024) pubmed
- Species-level verification of Phascolarctobacterium association with colorectal cancer. (2024) pubmed
- Complete genomes of Phascolarctobacterium faecium isolates obtained from pediatric mucosal-luminal interface aspirate samples. (2026) pubmed